New results, requirements for CMS's hospital value-based purchasing program

Most hospitals will see an increase in their fiscal year 2017 Medicare Severity Diagnosis-Related Group (MS-DRG) payments under CMS’s Hospital Value-Based Purchasing (VBP) program.

The FY2017 results from the program, which adjusts Medicare payments based on quality of care, said around 1,600 of the 3,000 hospitals participating will have a positive payment adjustment. The performing hospital in FY2017 will receive a net increase in payments of slightly more than 4 percent, and the lowest performing hospital will incur a net reduction of 1.83 percent.

Incentives in the Hospital VPB program depend on why well hospitals performed compared to their peers on important healthcare quality and resource use measures, like care coordination and safety, as well as how much a hospital has improved over time.

For FY2018, how those categories are weighted will change. Each of the four domains (Clinical Care, Patient Experience and Caregiver Centered Experience/Care Coordination, Safety, and Efficiency and Cost Reduction) will be weighted equally.

Parts of the measure set will change as well, like adding a “three-item Care Transition dimension,” which is part of the Hospital Consumer Assessment of Hospital Providers and Systems (HCAHPS) survey. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.